IQV · Iqvia Holdings Inc.

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026, at 9:20 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com . A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high quality health data, Healthcare grade AI ® , advanced analytics, the latest technologies,

IQVIA Holdings Inc. (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today published its 2025 Sustainability Report. The report highlights IQVIA’s progress across its People, Public and Planet pillars, consistent with the company’s mission to accelerate innovation for a healthier world. IQVIA’s 2025 Sustainability Report can be downloaded at: https://www.iqvia.com/-/media/iqvia/pdfs/about-us/sustainability/iqvia-2025-sustainability-report.pdf . Highlights from the report include: Investments in the company’s employees. IQVIA’s approximately 93,000 employees worldwide are central to delivering on the company’s mission. In 2025, IQVIA accelerated learning and development opportunities through expanded AI and data analytics upskilling, generating more than 230,000 employee engagements with AI learning resources. More than 2,000 employees

IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories. These assets include five sites specializing in a range of in vitro drug discovery services, including established laboratory based New Approach Methodologies (NAMs) and a small molecule AI platform, designed to accelerate discovery programs and support growing demand for non animal research methods. Collectively, these assets are underpinned by more than 20 years of curated scientific and operational data, as well as extensive therapeutic expertise. Since their inception, these assets have enabled over 100 molecules to enter clinical trials and include several commercially approved drugs. The acquisition complements IQVIA Laboratories’ existing drug discovery

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Ron Bruehlman, chief financial officer, and Mike Fedock, senior vice president, financial planning & analysis and incoming CFO, will speak at Citi's 2026 Unplugged MedTech and Life Sciences Access Day on Thursday, February 26, 2026, at 11:00 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com . A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and the Duke Clinical Research Institute (DCRI), one of the world’s largest academic clinical research organizations with extensive experience designing and operationally executing large, complex multi-center clinical trials, are pleased to announce their new collaboration to enhance the conduct of clinical research in obesity and related cardiometabolic trials. With the combined strength of two best-in-class organizations, this collaboration accelerates even the most sophisticated clinical programs and ensures coordinated, end-to-end support to sponsors, regulators, payers, patients and the broader medical community. By establishing the full operational framework up front, from governance to data flow to site-level execution, IQVIA and DCRI are able to quickly establish momentum on clinical trials with active

Revenue of $4,364 million for the fourth quarter, $16,310 million for the full year GAAP Net Income of $514 million for the fourth quarter, $1,360 million for the full year Adjusted EBITDA of $1,046 million for the fourth quarter, $3,788 million for the full year GAAP Diluted Earnings per Share of $2.99 for the fourth quarter, $7.84 for the full year Adjusted Diluted Earnings per Share of $3.42 for the fourth quarter, $11.92 for the full year R&D Solutions quarterly bookings of over $2.7 billion, representing a book-to-bill ratio of 1.18x R&D Solutions contracted backlog of $32.7 billion, up 5.3% year-over-year R&D Solutions Revenue of $2,333 million for the fourth quarter, up 9.9% year-over-year, $8,896 million for the full year, up 4.3% year-over-year TAS Revenue of $1,821 million for the fourth quarter, up 9.8% year-over-year, $6,626 million for the full year, up 7.6% year-over-year Operating Cash Flow of $735 million, bringing full-year Operating Cash Flow to $2,654

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced a strategic long-term collaboration with Boehringer Ingelheim. Boehringer Ingelheim has selected IQVIA’s Data-as-a-Service (DaaS+) technology offering as the accelerator to power its global commercial data harmonization and transformation journey. This collaboration will enable Boehringer Ingelheim to scale its commercial data products and analytics ambitions across therapeutic areas and regional teams, leveraging an industry-leading global data model. “We are excited about the possibilities of working with IQVIA’s Data as a Service (DaaS+) platform. By enabling the seamless ingestion of our global commercial data sets into a unified platform, directly integrated into our cloud infrastructure, we believe this platform would drive significant efficiencies in our data operations,

IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, was named No. 1 in its category on the 2026 Fortune ® World’s Most Admired Companies™ list. This is the fifth year in a row IQVIA has earned first place in the Health Care: Pharmacy and Other Services category, and the ninth consecutive year it has appeared on the list. Notably, IQVIA earned first place in its category on seven of the nine key attributes evaluated — innovation, people management, use of corporate assets, financial soundness, long-term investment value, quality of products/services and global competitiveness. “This recognition reflects the unwavering dedication and expertise of our employees worldwide. Their commitment to advancing innovation and improving global health supports the development of transformative medical treatments that enhance patient outcomes around the world,” said IQVIA Chairman and CEO Ari

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, will announce its fourth-quarter and full-year 2025 financial results before the market opens on Thursday, February 5, 2026. The IQVIA management team will also host a conference call and webcast at 9:00 a.m. Eastern Time that same day. The earnings release and accompanying financial information will be posted on the IQVIA Investor Relations website at: http://ir.iqvia.com . To listen to the event and view the presentation slides via webcast, join via the IQVIA Investor Relations website at: http://ir.iqvia.com . To participate in the conference call, interested parties must register in advance by registering on http://ir.iqvia.com . Following registration for the call, participants will receive a confirmation email containing details on how to join the conference call, including